The Imricor Medical Systems Inc (ASX: IMR) share price is edging higher today after news another hospital has purchased one of its products.
The post Imricor (ASX:IMR) share price rises on latest update appeared first on The Motley Fool Australia. –
The Imricor Medical Systems Inc (ASX: IMR) share price is edging higher today. As of writing, shares in the medical device company are trading for $2.10, up 2.94%. By comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is 0.4% higher.
Today’s positive price movement comes as the company advised another hospital has purchased one of its products.
Let’s take a closer look at the announcement and what it means for the Imricor share price.
Imricor company profile
Imricor is a medical device company that addresses issues with traditional x-ray-guided tissue removal procedures by developing MRI-guided technology. The company’s products include Advantage-MR EP recorder/stimulator, Vision-MR dispersive electrode, and its premier product, the Vision-MR ablation catheter.
According to the company, the ablation catheter is specifically designed to work under real-time MRI guidance to achieve “faster and safer treatment” than x-ray guidance.
What’s affecting the Imricor share price
In a statement to the ASX, Imricor announced Helios Hospital in Berlin, Germany, had signed a purchase agreement for an interventional cardiac magnetic resonance imaging (iCMR) lab to perform ablations with Imricor’s products. It is the 10th such hospital to sign an agreement with the company.
The medical imaging company did not disclose how much the deal was worth, or if there are any conditions to it. Despite this, investors are responding well to the news today, judging by the Imricor share price.
Imricor chair and CEO Steve Wedan said:
We are very pleased to add a second Helios hospital to our installed base, as Berlin-Buch joins the Helios Leipzig Heart Centre in adopting iCMR guided ablations.
While Europe continues a gradual recovery into a post COVID-19 era, we are very happy to be able to continue growing the number of centers [sic] enabled with Imricor’s solution for the future of cardiac electrophysiology.
The company expects operations with its products to begin at the hospital within a short period of time.
Imricor share price snapshot
Over the last 12 months, the Imricor share price appreciated 104.9%. However, it has fallen 22.4% over the last 6 months and 11.5% since February.
Imricor Medical Imaging has a market capitalisation of $240.2 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Worley (ASX:WOR) share price slides despite new contract
- Moderna just made the Pfizer vaccine’s biggest weakness an even bigger one
- Westpac (ASX:WBC) share price up 4%: Here’s an expert’s opinion
- Andromeda Metals (ASX:ADN) share price falls despite project update
- Archtis (ASX:AR9) share price jumps on defence contract
Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.